Skip to main content
Logo Mark
  • Research & Development
    • Telomerase Inhibition
    • Imetelstat
    • Publications
    • Clinical Trials
    • Healthcare Professionals
  • Patients
    • Expanded Access Protocol
  • Investors & Media
    • Press Releases
    • Events
    • Stock Information
    • Corporate Governance
    • SEC Filings
    • Analyst Coverage
    • FAQs
  • About
    • Leadership
    • Culture
    • History
    • Contact
  • Careers

Publications

Filter by:

Featured

Continuous Transfusion Independence with Imetelstat in Lower Risk MDS in IMerge Phase 3

Clinical Imetelstat: MDSImetelstat

EHA 2023

Platzbecker, et. al.

Analysis of Patient Reported Fatigue in IMerge Phase 3 Trial of Imetelstat vs. Placebo in Lower Risk MDS

Clinical Imetelstat: MDSImetelstat

EHA 2023

Sekeres, et. al.



All

    Improvement of Patient-Reported Fatigue in IMerge Phase 3 Trial of Imetelstat vs. Placebo in Heavily Transfused Non-del (5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents

    Clinical Imetelstat: MDSImetelstat
    SOHO 2023

    Sekeres, et. al


    Disease Modifying Activity of Imetelstat in Patients with Heavily Transfused Non-del (5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase 3

    Clinical Imetelstat: MDSImetelstat
    SOHO 2023

    Santini, et. al


    Continuous Transfusion Independence with Imetelstat in Heavily Transfused Non-del (5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase 3

    Clinical Imetelstat: MDSImetelstat
    SOHO 2023

    Platzbecker, et. al.


    Disease Modifying Activity of Imetelstat in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis Stimulating Agents in IMerge Phase 3

    Clinical Imetelstat: MDSImetelstat
    EHA 2023

    Santini, et. al.


    Continuous Transfusion Independence with Imetelstat in Lower Risk MDS in IMerge Phase 3

    Clinical Imetelstat: MDSImetelstat
    EHA 2023

    Platzbecker, et. al.


    Analysis of Patient Reported Fatigue in IMerge Phase 3 Trial of Imetelstat vs. Placebo in Lower Risk MDS

    Clinical Imetelstat: MDSImetelstat
    EHA 2023

    Sekeres, et. al.


    Modulation of the immune landscape in lower-risk myelodysplastic syndromes with imetelstat-induced transfusion independency

    Clinical Imetelstat: MDSImetelstat
    EHA 2023

    Chapuis, et. al.


    The telomerase inhibitor imetelstat differentially targets JAK2V617F- versus CALR-mutant Myeloproliferative Neoplasm cells and inhibits JAK-STAT signaling

    ImetelstatNon-clinical Imetelstat: MF
    EHA 2023

    Chatain, et. al.


    IMerge: Results From a Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Imetelstat in Patients with Lower-Risk MDS

    Clinical Imetelstat: MDSImetelstat
    ASCO 2023

    Zeidan, et al.


    MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

    Clinical Imetelstat: MFImetelstat
    ASH 2022

    Mascarenhas, et al.


    An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate-1, Intermediate-2 or High-Risk Myelofibrosis

    Clinical Imetelstat: MFImetelstat
    ASH 2022

    Bradley T, et al.


    Imetelstat Achieved Prolonged, Continuous Transfusion Independence in Patients With Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory to Erythropoiesis Stimulating Agents Within the IMerge Phase 2 Study

    Clinical Imetelstat: MDSImetelstat
    ASH 2022

    Platzbecker, et al.


    Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia

    ImetelstatNon-clinical Imetelstat
    ASH 2022

    Bruedigam C, et al.


    Pharmacological Inhibitory Effect of Imetelstat, A Novel Human Telomerase Inhibitor in Diffuse Large B-cell Lymphoma and Peripheral T-Cell Lymphoma

    ImetelstatNon-clinical Imetelstat
    Blood 2022

    Aradhya A, et al.


    Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design

    Clinical Imetelstat: MFImetelstat
    Future Oncology 2022

    Mascarenhas, et al.



Patients

We are on a mission to improve and extend lives

Discover more about our commitment to patients


Learn more
Explore
  • Research & Development
  • Pipeline
  • Partnering
  • Patients
Browse
  • Latest updates
  • Publications
  • Corporate profile
  • Press releases
  • Events
Learn
  • About
  • Leadership
  • Culture
  • History
Connect
  • Careers
  • Locations
  • Contacts
Follow
LinkedIn
Geron
  • Terms of Use
  • Privacy Policy
  • Cookie Policy

Copyright © 2023 Geron. All rights reserved

Back to top